Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2 :

Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2 : a randomised, double-blind, placebo-controlled, phase 1 trial / Keith J Chappell [and twenty four others]

Lancet Infect Dis . 2021 Apr 19;S1473-3099 (21) 00200-0.
doi: 10.1016/S1473-3099(21)00200-0.


COVID-19 Vaccines--immunology
Placebo Effects
Adjuvants, Immunologic